Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Excessive and prolonged alcohol consumption can lead to a serious health condition known as alcohol-related liver disease (ARLD). This ailment represents a significant worldwide health challenge, affecting populations across various demographics. ARLD has a multifactorial pathogenesis involving oxidative stress, inflammation, dysregulated lipid metabolism, and apoptosis. In this study, we investigated the hepatoprotective effects of L. leaf water extract (LLE) against ARLD in alcohol-treated hepatocytes and mice. LLE exhibited antioxidant and anti-inflammatory properties by enhancing antioxidant enzyme activities and suppressing proinflammatory cytokines and CYP2E1 expression in ethanol-treated hepatocytes. Moreover, LLE mitigated lipogenesis by modulating the expression of lipogenic factors in ethanol-treated hepatocytes. , LLE administration attenuated liver injury, oxidative stress, inflammation, and lipid accumulation induced by alcohol consumption in mice. Additionally, LLE suppressed apoptosis signaling pathways implicated in alcohol-induced hepatocyte apoptosis. These findings suggest that LLE functions as a multifaceted therapeutic agent for ARLD by modulating multiple cellular mechanisms, including the reduction of oxidative damage, mitigation of inflammatory responses, alleviation of lipid-mediated toxicity, and regulation of programmed cell death pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/jmf.2024.k.0111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.
Liver Int
October 2025
CHU Amiens Picardie, Service D'hépato-gastroentérologie, Amiens, France.
Background And Aims: Atezolizumab-Bevacizumab (AtezoBev) was the first immunotherapy approved for hepatocellular carcinoma (HCC) in France, with initial trials primarily involving patients with viral-related liver disease. This prospective study aimed to evaluate the efficacy of AtezoBev in a French HCC population predominantly affected by non-viral liver disease.
Methods: Data from 545 HCC patients treated with AtezoBev as first-line systemic therapy were collected from 32 French centres in the CHIEF cohort between July 2020 and January 2023.
Diagnosed Patients With Chronic Hepatitis B and Delta Virus in Italy in 2024: An Estimation From a National Real-World Database.
Liver Int
October 2025
Gastroenterology, Hepatology and Transplantation Division, ASST Papa Giovanni XXIII, Bergamo, Italy.
Background And Aims: Hepatitis B (HBV) and Hepatitis Delta virus (HDV) infection have undergone significant changes in Italy over the past few decades, but reliable and updated prevalence of chronic hepatitis B (CHB) and Delta (CHD) data are lacking. The aim of the study was to describe the epidemiology of CHB and CHD in Italy in 2024, based on real-world data.
Methods: The number of patients with a healthcare expenditure exemption for CHB (016.
Cross-continental immunity: unraveling hematological markers of HIV in Africa and Russia- a perspective.
Ann Med Surg (Lond)
September 2025
Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.
Hematological abnormalities are common in individuals living with HIV, and these complications vary significantly across global populations due to diverse genetic, environmental, and socio-economic factors. This review explores the divergent immunohematological trends observed in HIV-infected populations in Africa and Russia, focusing on key hematological markers such as anemia, thrombocytopenia, and neutropenia. While both regions experience high burdens of HIV, their populations present with distinct hematological manifestations influenced by co-infections, lifestyle factors, and local healthcare systems.
View Article and Find Full Text PDFPrevalence, risk factors, and metabolic implications of alcohol use disorders among male workers in Hebei Province, China: a cross-sectional study.
Subst Abuse Treat Prev Policy
September 2025
Department of Psychiatry, the First Hospital of Hebei Medical University, No.89 Donggang Road, Shijiazhuang, 050031, China.
Background: Alcohol is a psychoactive substance that can lead to alcohol use disorders (AUDs), which encompass a spectrum of conditions including alcohol dependence and abuse, causing significant mental and physical health issues. Excessive drinking is linked to various diseases, such as liver damage, metabolic disorders, and mental health conditions, with notable gender differences in drinking patterns, particularly among workers. This study investigates the prevalence, risk factors, and metabolic implications associated with AUDs among male workers in China.
View Article and Find Full Text PDFFucoidan from alleviates MetALD via promoting HIF-1α ubiquitination to suppress peripheral monocyte infiltration.
Front Pharmacol
August 2025
Institute of Molecular Immunology, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangdong Province Key Laboratory of Immune Regulation and Immunotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
Metabolic and alcohol-related liver disease (MetALD), characterized by excessive alcohol intake in individuals with metabolic dysfunction, is a growing health burden worldwide. Hepatic macrophages play a pivotal role in MetALD pathogenesis, with pro-inflammatory infiltrating monocytes/macrophages contributing to liver injury. Fucoidan, a sulfated polysaccharide derived from brown algae, is known for its anti-inflammatory properties, yet its intracellular targets remain poorly defined.
View Article and Find Full Text PDF